Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
TFI International enters its October 23 Q3 earnings window with a sharp short-interest build and a stock down 15% over the past month, yet the lending market is signalling far less conviction than the headline numbers might suggest.
The standout development since last week's note is the jump in shares short. Short interest climbed 38% in a single session on October 6, taking it to 1.27 million shares, or 1.5% of free float. That is the highest level in the 30-day window and continues the trend flagged a week earlier, when short interest was running at roughly 920,000 shares. The one-month increase is now 33%. For context, though, 1.5% of free float is still a low absolute level. This is a build from near-nothing, not a crowded short. The borrow market reinforces that read. Cost to borrow has actually fallen sharply this week, dropping to 0.67% from 1.26% last Friday, giving back most of the spike seen around September 29 that was highlighted in the previous note. Availability has simultaneously loosened to nearly 7,854% of short interest, with over 63 million shares available to borrow against barely 1.3 million shares short. The lending pool has more room than it has had all month, a very different picture from the brief tightness seen in late September. The ORTEX short score has eased to 29.7 from a recent high of 32.4, drifting in the wrong direction for bears despite the rise in shares short.
The Street picture is harder to read cleanly. Analyst data in the snapshot is stale, last updated in September 2023, so no current price targets or recent rating changes can be cited with confidence. What the factor scores do show is a company with strong earnings revision momentum: the 12-month forward EPS growth rank sits in the 92nd percentile, and 30-day and 90-day EPS momentum scores are 78 and 87 respectively. The valuation, however, has compressed alongside the share price. The price-to-earnings multiple has fallen roughly 2.9 points over the past 30 days to about 15.4x, and the price-to-book is down 0.5 points to 3.1x. EV/EBITDA has drifted down to 8.5x. The direction of travel in multiples reflects the stock's 15% one-month slide rather than a de-rating driven by earnings cuts. Among peers, XPO was the week's outperformer with a 3.5% gain, while SNDR fell 1.2% and HTLD dropped 2.7%. TFII's 5.9% weekly decline was one of the sharper moves in the group.
Ownership is notable for its stability. CEO and founder Alain Bedard holds close to 6% of shares outstanding, a stake that has not changed. La Caisse de dépôt et placement du Québec, the Quebec pension fund, holds 7.7% and most recently disclosed a further increase when it filed a 13G/A amendment in February 2026, moving its stake from 6.9% to 8.6%. No 13D activist is on the register. The insider picture over the past 90 days is net negative: sales have outweighed purchases by roughly CAD 11.6 million in value. The most recent disclosed open-market activity was a director purchase by Rosemary Turner in August, roughly $1 million across two transactions at around $140 per share. Those purchases are now underwater at the current CAD 161.80 price.
Earnings history adds some caution. The July 2026 Q2 report saw the stock fall 1.6% the next day and 6.2% over the following five sessions. An earlier Q1 print produced a 2.6% day-one gain but a fractional loss by day five. The pattern suggests the stock has struggled to hold post-earnings pops, with the five-day window the more meaningful test.
With the October 23 print now 16 days away, the tension to watch is whether the short interest build continues at the same pace. A second consecutive 38% single-session jump would push the position toward 2% of float and begin to look more purposeful. For now, with borrow costs falling and availability near its widest level of the month, positioning looks cautious rather than crowded.
See the live data behind this article on ORTEX.
Open TFII on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
